Skip to content

Clinical trials

Phase 1 Lung Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Neoplasms Phase: Phase 1 Clear all

622 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200017
20014
20029
200315
200415
200513
200621
200722
200821
200930
201017
201114
201218
201313
201417
201517
201627
201725
201820
201928
202022
202140
202230
202330
202442
202530
202622

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed296
Terminated94
Recruiting77
Active, not recruiting54
Unknown status46
Withdrawn27
Not yet recruiting19
Suspended8
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)41
M.D. Anderson Cancer Center25
Memorial Sloan Kettering Cancer Center18
Pfizer15
Jonsson Comprehensive Cancer Center11
Novartis Pharmaceuticals11
Roswell Park Cancer Institute10
Emory University9
H. Lee Moffitt Cancer Center and Research Institute8
City of Hope Medical Center7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Neoplasms622
Carcinoma, Non-Small-Cell Lung307
Breast Neoplasms152
Neoplasms105
Ovarian Neoplasms105
Colorectal Neoplasms100
Pancreatic Neoplasms96
Melanoma75
Neoplasm Metastasis75
Head and Neck Neoplasms67

Trials

Showing 26 to 50 of 622. Each trial links to its page on Pharma Observatory.

522 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.